Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent. Traditional Pre-Clinical Safety End Points Failed to Predict 6-Month Clinical Angiographic Results

JACC: Cardiovascular Interventions

Volumn 2, Issue 10, 2009, Pages 1017-1024

  Ormiston, John A ^a,b,c   Webster, Mark W I ^a,b,c   Schwartz, Robert S ^d   Gladding, Patrick ^c   Stewart, James T ^a,b,c   Kay, I Patrick ^a   Ruygrok, Peter N ^a,b,c   Hatrick, Robert ^c  

^a Mercy Angiography   (New Zealand)

^b Auckland Radiology Group   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

anti inflammatory; drug eluting stent; pimecrolimus; pre clinical; restenosis

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DEATH; DRUG ELUTING STENT; FEASIBILITY STUDY; FEMALE; HEART INFARCTION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MALE; MULTICENTER STUDY; NONHUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS; SWINE; THERAPY EFFECT;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; NEW ZEALAND; POLYMERS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SWINE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; XYLENES;

EID: 70350008278     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.08.006     Document Type: Article

References (27)

1. Moses J., Leon M., Popma J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1351-23
2. Stone G., Ellis S., Cox D., et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Costa M., and Simon D. Molecular basis of restenosis and drug-eluting stents. Circulation 111 (2005) 2267-2273
4. Farb A., and Boam A. Stent thrombosis redux- the FDA perspective. N Engl J Med 356 (2007) 984-987
5. Curfman G., Morrissey S., Jarcho J., and Drazen J. Drug-eluting stents-promise and uncertainty. N Engl J Med 356 (2007) 1059-1060
6. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G., and Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
7. Finn A., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
8. Welt F., and Rogers C. Inflammation and restenosis in the stent era. Atherioscler Thromb Vasc Biol 22 (2002) 1769-1776
9. Farb A., Weber D., Kologie F., et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105 (2002) 2974-2980
10. Waksman R., Pakala R., Baffour R., et al. Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. Cardiovasc Revasc Med 8 (2007) 259-274
11. Berg R., Aragon J., Royter V., et al. Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. Cathet Cardiovasc Interv 70 (2007) 871-879
12. Abizaid A., Alberal M., Ormiston J., et al. IMPACT trial: angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer stent system. Cathet Cardiovasc Interv 66 (2005) 491-495
13. Guidance for Industry. Q3B(R2) Impurities in New Drug Products. http://www.fda.gov/cder/guidance/7385fnl.htm Accessed July 22, 2007
14. Carter A., Aggarwal M., Kopia G., et al. Long-term effects of polymeric slow release sirolimus eluting stents in the porcine coronary model. Cardiovasc Res 63 (2004) 614-624
15. Suzuki T., Kopia G., Hayashi S., et al. Stent-based sirolimus therapy reduces neointimal formation and In-stent restenosis in a porcine coronary model. Circulation 104 (2001) 1188-1193
16. Joner M., Finn A., Farb A., et al. Pathology of drug-eluting stents in man: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
17. Virmani R., Kolodgie F., Farb A., and Lafont A. Drug eluting stents: are human and animal studies comparable?. Heart 89 (2003) 133-138
18. Schwartz R., Edelman E., Carter A., et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
19. Verheye S., Agostoni P., Dawkins K., et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. J Am Coll Cardiol Intv 2 (2009) 205-214
20. Costa R., Lansky A., Abizaid A., et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 98 (2006) 443-446
21. Hoffman R., Kangenber R., Radke P., et al. Evaluation of high-dose dexamethasone-eluting stent. Am J Cardiol 94 (2004) 193-195
22. Lincoff A., Furst J., Ellis S., Tuch R., and Topol E. Sustained local delivery of dexamethasone by novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 193-195
23. Berk B., Gordon J., and Alexander R. Pharmacological roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 17 Suppl B (1991) 111B-117B
24. Pepine C., Hirshfeld J., Macdonald R., et al. Controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 81 (1990) 1753-1761
25. Holmes Jr. D.R., Savage M., LaBlanche J.M., et al. Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 106 (2002) 1243-1250
26. Rzucidio E., Martin K., and Powell R. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 45 Suppl A (2007) A25-A32
27. Bauriedel G., Jabs A., Kraemer S., Nickenig G., and Skowasch D. Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristics. J Vasc Res 45 (2007) 173-178